Interview: AstraZeneca ‘Is More Than Oncology’

AZ’s BioPharma Unit Head Points To CVRM And Respiratory Promise

28 Oct 2019

• By Sten Stovall

Ruud Dobber oversees AstraZeneca’s biopharmaceuticals division, which generates some 40% of group total revenues. He tells Scrip to “Watch this space.”

Three_Pipes — AstraZeneca’s Three Therapy Areas Are Cancer, CVRM and Respiratory • Source: Shutterstock

While clearly enjoying the rewards of its a strengthening oncology portfolio, AstraZeneca PLC also used its third-quarter results update 24 October to stress that its two other therapeutic pillars - respiratory and CVRM - are performing well and hold great promise.

“Yes, we are very proud of our oncology performance at AstraZeneca, but equally we’re trying to signal that AstraZeneca is...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Finance Watch: Insmed Cashes In On Positive Data With $750m Offering

12 Jun 2025

• By Mandy Jackson

Public Company Edition: Insmed raised $750m after reporting positive Phase IIb data in PAH, Cogent accessed up to $400m in new debt, Kelun-Biotech netted $250m in a placement of shares and ADC revealed a $100m private placement. In strategic updates, Recursion cut 20% of its jobs.

Lilly Looks For Muscle-Sparing Candidates In Pact With Juvena

12 Jun 2025

• By Joseph Haas

Deal Snapshot: Including its internal efforts with bimagrumab, Lilly has been seeking a muscle-sparing therapy to complement GLP-1 obesity drugs, such as Zepbound.

Asia Deal Watch: Otsuka’s Taiho Licenses LSD1 Inhibitor Rights To Benz

12 Jun 2025

• By Joseph Haas, Lisa Takagi, Jung Won Shin, Vibha Ravi, and Sushmita Panda

Plus deals involving BioAge/JiKang, Sanyou/Medicovestor, AriBio/Acino, Intragrand/Transpire, Kaken/Twocells, Sumitomo/Novo Nordisk, NIBEC/Undisclosed, Formosa/Adalvo, Drug Farm/Amoytop, Lupin/SteinCares and Lupin/Honeywell.